The USFDA issued six observations to Granules India’s Gagillapur facility in Hyderabad after an inspection between August 26 and September 6. The company is committed to addressing these issues promptly and will submit its response within the stipulated time frame. Following this news, Granules India’s stock fell by over 16% on the BSE.
Related Posts
India expected to remain stable amid US China trade war in 2025: Goldman Sachs
Goldman Sachs predicts India’s economy will experience a cyclical slowdown, with GDP growth decelerating to 6.3 percent by 2025. Despite this, the country is expected […]
India among top sources for job applications: Riyadh Air
- staff
- March 12, 2025
- 0
India is a major contributor to applications for Riyadh Air, Saudi Arabia’s upcoming second national carrier. Despite not announcing salary structures, the airline has received […]